B2B
Upstream Bio
Waltham, United Statesupstreambio.com
Upstream Bio is developing verekitug, a clinical-stage antagonist targeting the TSLP receptor to treat chronic respiratory diseases driven by inflammation, such as severe asthma, CRSwNP, and COPD.
aliveseries-c-plus
series-c-plus
Stage
2018
Founded
2
Funding Rounds
About
Upstream Bio is developing verekitug, a clinical-stage antagonist targeting the TSLP receptor to treat chronic respiratory diseases driven by inflammation, such as severe asthma, CRSwNP, and COPD.
Explore Upstream Bio's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.